Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2778 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-18

Study Completion Date

2023-07-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking

NCT03958071

Idiopathic Pulmonary Fibrosis

COMPLETED

Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients

NCT05022784

Idiopathic Pulmonary Fibrosis

COMPLETED

Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary Fibrosis

NCT06650774

Idiopathic Pulmonary Fibrosis (IPF)

COMPLETED

The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis

NCT02009293

Idiopathic Pulmonary Fibrosis

COMPLETED

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

NCT05875532

Lung Diseases, Interstitial

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pirfenidone initiators cohort

IPF patients from the Optum Research Database (ORD) who presented at least one pirfenidone prescription during the identification period (the date of first prescription for pirfenidone was considered the index date, between October 2014 up to December 2021) and with at least 12 months of continuous enrollment in the health plan during pre-and post-index period.

Pirfenidone

Intervention Type DRUG

Pirfenidone

Nintedanib initiators cohort

IPF patients from the Optum Research Database (ORD) who presented at least one nintedanib prescription during the identification period (the date of first prescription for nintedanib was considered the index date, between October 2014 up to December 2021) and with at least 12 months of continuous enrollment in the health plan during pre-and post-index period.

Nintedanib

Intervention Type DRUG

Nintedanib

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pirfenidone

Intervention Type DRUG

Nintedanib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of at least one pirfenidone or nintedanib prescription during the identification period (0/01/2014 to 09/30/2021; the date of first prescription for pirfenidone/nintedanib is the index date)
* Evidence of IPF: patient with at least one inpatient or two outpatient claims (\>14 days apart) with a diagnosis code for IPF during the study period (10/01/2013 to 09/30/2022)
* At least 18 years old at the index date
* Have at least 12 months of continuous enrollment in the health plan during pre-index period, and at least 6 months of continuous enrollment in post-index period

Exclusion Criteria

* Any history of lung transplant during the 12-months pre-index/baseline period
* Any claims for a skilled nursing facility, a long-term care facility or hospice care during the 12-month pre-index period
* Evidence of non-IPF chronic fibrosis Interstitial Lung Disease (ILD) or connective tissue diseases during the 12-months pre-index period. The following conditions will be excluded: autoimmune, or connective tissue diseases (i.e., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatopolymyositis, systemic sclerosis, Sjogren's syndrome, and mixed connective tissue disease (CTD), sarcoidosis, and hypersensitivity pneumonitis).
* Missing demographic information (i.e., age or sex)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No